Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

14.60
+0.16001.11%
Pre-market: 15.450.8500+5.82%04:30 EDT
Volume:156.61K
Turnover:2.30M
Market Cap:378.24M
PE:-3.25
High:15.84
Open:14.19
Low:13.57
Close:14.44
Loading ...

Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership

TIPRANKS
·
27 Feb

Yale University Exits Cartesian Therapeutics Inc, Impacting Portfolio by -66.5%

GuruFocus
·
15 Feb

Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics

TIPRANKS
·
29 Jan

Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design

MT Newswires Live
·
27 Jan

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Dow Jones
·
27 Jan

Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials

TIPRANKS
·
27 Jan

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis

THOMSON REUTERS
·
27 Jan

Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics

TIPRANKS
·
15 Jan

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Dow Jones
·
14 Jan

Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability

TIPRANKS
·
14 Jan

BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities

Reuters
·
13 Jan

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027

THOMSON REUTERS
·
13 Jan

Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25

THOMSON REUTERS
·
13 Jan

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?

Zacks
·
13 Jan